Curvebeam Ai Ltd. · ASX:CVB
Curvebeam Ai — Investor Presentation (August 2024)
38 slides from Curvebeam Ai's investor presentation, Aug 1, 2024
Slide 1: Investor Presentation
INVESTOR PRESENTATION July 2024
Slide 2: Disclaimer
DISCLAIMER Introduction market and industry trends, which are based on interpretations of current market conditions, may not be reasonable, and are not THIS DOCUMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR guarantees or predictions of future performance. IND
Slide 3: Investment Highlights
CURVEBEAM AI IS A MEDICAL DEVICE INVESTMENT COMPANY FOCUSED ON COMMERCIALISING WEIGHT BEARING CT SCANNERS & AI SAAS HIGHLIGHTS SOLUTIONS • First to market, bilateral weight bearing CT scans First to market • Enhanced HiRiseTM CT provides in-office high-resolution 3D scans & future AI aided clinical
Slide 4: Executive Summary
E X E C U T I V E S U M M A RY CurveBeam AI is a medical device company focused on commercialising weight bearing CT scanners • Weight Bearing CT (WBCT) provides 3D scans of joints under weight, enabling visualisation and assessment of condition under weight Products & solutions • The high resolutio
Slide 5: Company Overview
01 C O M PA N Y O V E R V I E W 5 INVESTOR PRESENTATION
Slide 6: CurveBeam AI CT Devices & AI Output
CURVEBEAM AI CT DEVICES & AI OUTPUT CurveBeam AI has a range of CT imaging devices with visualisation applications in orthopaedics and bone health STRAXCORP – KEY POINTS ORTHOPAEDIC VISUALISATION & PLANNING BONE HEALTH CLINICAL AIDS What do we do? Addressing a major underserved healthcare crisis • B
Slide 7: CurveBeam Technology Platform Overview
C U R V E B E A M T E C H N O L O G Y P L AT F O R M O V E R V I E W CurveBeam AI has regulatory clearances for WBCT devices in-market, including the new Enhanced HiRiseTM – CVB targeting first automated BMD report for surgical planning for mid 2025 REGULATORY/ US MARKET GROSS REVENUE SOLUTION PRODU
Slide 8: Weight Bearing CT
02 WEIGHT BEARING CT 8 INVESTOR PRESENTATION
Slide 9: Weight Bearing CT Overview
WEIGHT BEARING CT OVERVIEW ü Quicker and easier to scan than traditional CT and MRI, ü Radiation dose lower than traditional CT – up to 66% less than with faster image acquisition time traditional CT ü High resolution and 3D visualisation enables ü Smaller and lower-cost hardware requiring limited r
Slide 10: HiRise in Action (Video)
HIRISE IN ACTION (VIDEO) 10 I N V E S T O R P R E S E N T A T I O N
Slide 11: AI Modules Will Target Subscription Based SaaS
A I M O D U L E S W I L L TA R G E T S U B S C R I P T I O N B A S E D S A A S CubeVue AutoMetrics aims to reduce hours of surgeon time for pre-surgical planning to a scan available in 15 minutes APPLICATIONS THE PROBLEM THE SOLUTION • Suspected hip, knee and • Orthopaedic pre-treatment planning inv
Slide 12: Strong Investment Proposition for Surgeons
STRONG INVESTMENT PROPOSITION FOR SURGEONS Targeting existing reimbursement codes - creates an attractive financial model • The average Medicare reimbursement rate for scans of the lower extremity CPT code relevant to the HiRise™, pedCAT™ and LineUP™ was US$138.77 per scan in 2022 Atlantic Orthopaed
Slide 13: Regulatory & Reimbursement Overview
R E G U L AT O RY & R E I M B U R S E M E N T O V E R V I E W Over 10 years of regulatory and clinical development and clearances underpin CurveBeam AI’s industry leading position • FDA cleared, CE Marked and ARTG listed for HiRise - allows sales of HiRise in key markets – e.g. US, Europe and Austra
Slide 14: Stryker F&A Partnerships
03 S T RY K E R F & A PA R T N E R S H I P 14 I N V E S T O R P R E S E N T A T I O N
Slide 15: Stryker Foot & Ankle Co-Marketing & Distribution US Partnership
STRYKER FOOT & ANKLE CO-MARKETING & DISTRIBUTION US PARTNERSHIP US F&A division has access to 500 reps and 40 regional Sales Managers STRYKER CORPORATION (NYSE:SYK) BACKGROUND • Leading Orthopaedics & Spine multinational (NYSE) (MC circa US$130B) • CurveBeam AI agreement is with the Foot & Ankle (F&
Slide 16: Commercialisation Strategy
04 C O M M E R C I A L I S AT I O N S T R AT E G Y 16 I N V E S T O R P R E S E N T A T I O N
Slide 17: Large Market Opportunity & Adoption by Leading Customers
LARGE MARKET OPPORTUNITY & ADOPTION BY LEADING CUSTOMERS Potential US Addressable Market ~17,000+ potential Customers3 Examples installations (WBCT scanners only)1 (A$bn)2 • Mayo Clinics (all 3 major locations) Hospital Based • NYU Langone Health A$3.4bn • Medium to large hospitals – can • UCLA Orth
Slide 18: BMD and OssView Overview
S TA G E 1 – S E C O N D F X B U S I N E S S M O D E L An over 60 yr old fracture patient suspected of fragility fracture goes to FLS – non-osteoporosis – Impact or Fragi BMD AND OSSVIEW OVERVIEW AWS AI SaaS solutions for CT scans – an automated BMD result for surgical planning Step 1 Step 2 Step 3
Slide 19: Two Business Models
TWO BUSINESS MODELS Existing reimbursement codes/coverage targeted to drive both business models 1. Present HiRise CT Business Model • Stryker sells HiRise for US$410,000 (circa A$645,000) Daily patient volume through a USA group surgeon office • CurveBeam AI transfers HiRise to Stryker • Targeting
Slide 20: Land & Expand Commercialisation Strategy
L A N D & E X PA N D C O M M E R C I A L I S AT I O N S T R AT E G Y Over 170 first & second-generation installations worldwide, CurveBeam AI is well placed to upgrade its global install base • ~17,000+ potential installations NORTH AMERICA EUROPE • Utilises a combination of specialist Operations HQ
Slide 21: FY24 Quarterly Purchase Orders
F Y 2 4 Q U A R T E R LY P U R C H A S E O R D E R S CurveBeam AI LineUp and PedCat WBCT devices are no longer available - stock is now sold Global WBCT purchase orders 10 7 6 4 4 3 3 3 3 3 0 0 FY24 Q1 FY24 Q2 FY24 Q3 FY 24 Q4 Total o rders HiRIse Lin eUp/P edCat 21
Slide 22: Next Generation WBCT Platform: SkyRise
Next Generation WBCT Platform: SKYRISE TM • SkyRise targets scans for dynamic structural detail about spinal alignment, joint orientation and supporting muscles. With future bone density & microstructure measures for better planning • AI will target vertebrae with anatomical landmark recognition – t
Slide 23: Experienced Board and Management
05 EXPERIENCED BOARD AND MANAGEMENT 23 I N V E S T O R P R E S E N T A T I O N
Slide 24: Experienced Board
EXPERIENCED BOARD ROBERT LILLEY GREGORY BROWN ARUN SINGH HASHAN DE SILVA KATE ROBB Non-Executive Chairman, Chief Executive Officer, Executive Director, COO, CTO- Non-Executive Director, Non-Executive Director BA (Yale) B.app.Sc, MBA CT, US president BSc (Medicine), MCom, CFA BBus (Accounting), CA, •
Slide 25: Senior Management
SENIOR MANAGEMENT URA P AUCKLAND YU PENG S. TURNER DEAN VINTI SINGH CFO, Company Secretary CTO-AI, BSc & PhD Chief Sales Officer Vice President of Marketing, • B.Bus, G.Dip Company • Over 15 years’ experience in • 45 years of experience in BA (Journalism), MBA Secretarial Practice, Columbia computer
Slide 26: Near Term Catalysts
06 N E A R T E R M C ATA LY S T S 26 I N V E S T O R P R E S E N T A T I O N
Slide 27: Milestones Over the Next 24 Months
MILESTONES OVER THE NEXT 24 MONTHS 510(k) FDA clearance for the Pre meeting on CVB BMD with Launch Autometrics FDA Clearance for BMD SaaS Enhanced HiRise, submitted FDA, and then conducting the module SaaS model Jun-24 under special 510(k) agreed clinical trial/s for BMD FDA clearance clearance subm
Slide 28: WBCT Competitors - PlanMed Verity & XFI
WBCT COMPETITORS - PLANMED VERITY & XFI PlanMed Verity XFI – WBCT – in development/future competition • Available today – FDA, CE, TGA • No known regulatory clearances to date • Partial foot, Ankle, knee • Space & height is considered to limit access to group surgeon settings • Unilateral and not na
Slide 29: The Offer
07 THE OFFER 29 I N V E S T O R P R E S E N T A T I O N
Slide 30: Offer Summary
OFFER SUMMARY CurveBeam AI is seeking to raise approximately A$13.6 million via the issue of approximately 75.6 million new fully paid ordinary shares (“New Shares”) • An institutional two-tranche Placement to raise up to approximately A$4.0 million (“Placement”); Offer structure and size • A 1 for
Slide 31: Use of Proceeds & Funding
USE OF PROCEEDS & FUNDING Sources of funds A$m Uses of funds A$m Placement 4.0 Sales & Marketing 4.6 Entitlement Offer1 5.9 Research & Development Expenses 2.1 Working Capital 2.3 Transaction Costs 0.9 Total 9.9 Total 9.9 Funding A$m Cash as at 30 June 2024 6.4 Net proceeds from capital raise 9.0 Pr
Slide 32: Indicative Offer Timetable
INDICATIVE OFFER TIMETABLE Item Date Trading Halt and Appendix 4C released to ASX Wednesday, 31 July 2024 Institutional Placement and Institutional Entitlement Offer opens and announced to the market Thursday, 1 August 2024 Institutional Placement and Institutional Entitlement Offer closes Friday 2
Slide 33: Appendix
08 APPENDIX 33 I N V E S T O R P R E S E N T A T I O N
Slide 34: Key Investment Risks
KEY INVESTMENT RISKS Regulatory clearances Reimbursement availability Market acceptance • The Group will require, and intends to apply for, further regulatory • The commercial success of the Group’s products and services is critically • Sales of the Group’s products and services depends on the exten
Slide 35: Key Investment Risks
KEY INVESTMENT RISKS Protection of IP Additional funding risk Reliance on distributors • If the Group is unable to protect its IP, its competitors could develop and • The Group may need to raise additional funds in the future to support its • CurveBeam relies on distributors to distribute its produc
Slide 36: Key Investment Risks
KEY INVESTMENT RISKS Cybersecurity and data protection risks Taxation matters (post-merger) Patient safety and product liability • Laws relating to data privacy are evolving across all jurisdictions. Data • The merger agreement includes a mechanism pursuant to which a portion • The Group faces produ
Slide 37: Offer Jurisdictions
OFFER JURISDICTIONS This document does not constitute an offer of new ordinary shares (“New Shares”) of the Company in any Other than in the entitlement offer, the New Shares may only be offered or sold in New Zealand (or allotted with a jurisdiction in which it would be unlawful. In particular, thi
Slide 38: Thank You
THANK YOU